Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy Thomas J. Smith, MD, Patrick J. Coyne, RN, MSN, Gwendolyn L. Parker, RN, MSN, Patricia Dodson, BSN, MA, Viswanathan Ramakrishnan, PhD Journal of Pain and Symptom Management Volume 40, Issue 6, Pages 883-891 (December 2010) DOI: 10.1016/j.jpainsymman.2010.03.022 Copyright © 2010 Terms and Conditions
Fig. 1 The MC5-A Calmare® device positioned to treat stocking-glove neuropathy. Journal of Pain and Symptom Management 2010 40, 883-891DOI: (10.1016/j.jpainsymman.2010.03.022) Copyright © 2010 Terms and Conditions
Fig. 2 Effect of MC5-A Calmare® therapy on pain scores during treatment. P<0.0001 by paired t-test, two-tailed. Journal of Pain and Symptom Management 2010 40, 883-891DOI: (10.1016/j.jpainsymman.2010.03.022) Copyright © 2010 Terms and Conditions
Fig. 3 Effect of MC5-A Calmare® therapy on pain scores. Overall reduction in pain score is 64%; P<0.001 by repeated-measures analysis of variance. Journal of Pain and Symptom Management 2010 40, 883-891DOI: (10.1016/j.jpainsymman.2010.03.022) Copyright © 2010 Terms and Conditions
Fig. 4 Duration of effect of MC5-A Calmare® therapy on pain scores: pain relief over time. Journal of Pain and Symptom Management 2010 40, 883-891DOI: (10.1016/j.jpainsymman.2010.03.022) Copyright © 2010 Terms and Conditions